Avalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.
4 reports, 3 independent
Updated Fri 00:00
Still developing
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Avalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Leerink Partners started coverage on Avalo Therapeutics and CFO Christopher Sullivan sold stock.1 source
Avalo Therapeutics received mixed ratings and coverage from major financial institutions.1 source
Keep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald reiterated an overweight rating on BioPharma shares, reducing the target price and setting a buy rating.
- Raymond James Financial and Cantor Fitzgerald issued buy/overweight ratings on Ulta Beauty stock.
- Cantor Fitzgerald started coverage and upgraded its rating from strong sell to sell for Critical Metals Corp. on September 12, 2026.
- MarketBeat reported on analyst coverage for IONQ, noting that Needham reiterated its buy rating, while Cantor Fitzgerald set a $70.00 price target and reiterated its overweight rating.
- Analyst provides a high price target for Viking Therapeutics stock.